Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCTFree Report) in a research note released on Saturday morning. The firm issued a hold rating on the stock.

Separately, HC Wainwright reduced their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a research note on Monday, August 12th.

View Our Latest Analysis on Oncternal Therapeutics

Oncternal Therapeutics Price Performance

Shares of ONCT opened at $4.16 on Friday. The firm has a market capitalization of $12.31 million, a PE ratio of -0.34 and a beta of 1.36. The company has a 50-day simple moving average of $5.98 and a two-hundred day simple moving average of $7.77. Oncternal Therapeutics has a one year low of $3.25 and a one year high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCTGet Free Report) last released its earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.03) by $0.14. The company had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $0.24 million. Oncternal Therapeutics had a negative net margin of 1,948.70% and a negative return on equity of 136.10%. During the same quarter in the previous year, the company earned ($3.00) EPS. Analysts expect that Oncternal Therapeutics will post -11.4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCTFree Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 16.05% of the company’s stock.

About Oncternal Therapeutics

(Get Free Report)

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.

Further Reading

Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.